Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: Clinical significance and improved characterization

Journal of Nuclear Medicine

Volumn 47, Issue 4, 2006, Pages 609-615

  Joon, Young Choi ^a   Kyung, Soo Lee ^a   Kim, Hyung Jin ^a   Young, Mog Shim ^a   Kwon, O Jung ^a   Park, Keunchil ^a   Baek, Chung Hwan ^a   Jae, Hoon Chung ^a   Lee, Kyung Han ^a   Kim, Byung Tae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

18F FDG; Incidentaloma; PET; PET CT; Thyroid

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANAMNESIS; ARTICLE; ASPIRATION BIOPSY; CANCER RISK; CLINICAL FEATURE; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ECHOGRAPHY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PAPILLARY CARCINOMA; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; ROC CURVE; THYROID CANCER; THYROID DISEASE; DIFFERENTIAL DIAGNOSIS; IMAGE PROCESSING; IMAGE SUBTRACTION; METASTASIS; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREVALENCE; RADIOGRAPHY; RISK ASSESSMENT; SCINTISCANNING; THYROID NODULE; THYROID TUMOR;

ADULT; BIOPSY, FINE-NEEDLE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SUBTRACTION TECHNIQUE; THYROID NEOPLASMS; THYROID NODULE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33745103803     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Burguera B, Gharib H. Thyroid incidentalomas: prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 2000;29:187-203.
2. Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a random adult population. Radiology. 1991;181:683-687.
3. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med. 1994;154:1838-1840.
4. Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med. 1992;93:359-362.
5. Sasaki M, Ichiya Y, Kuwabara Y, et al. An evaluation of FDG-PET in the detection and differentiation of thyroid tumours. Nucl Med Commun. 1997;18:957-963.
6. Kresnik E, Gallowitsch HJ, Mikosch P, et al. Fluorine-18- fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery. 2003;133:294-299.
7. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130:941-946.
8. 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003;88:4100-4104.
9. 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res. 2005;25:1421-1426.
10. Yi JG, Marom EM, Munden RF, et al. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology. 2005;236:271-275.
11. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
12. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357-4368.
13. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998;207:775-778.
14. 18F]fluorodeoxyglucose positron emission tomography of the thyroid gland. Nucl Med Commun. 2003;24:1225-1230.
15. Solbiati L, Osti V, Cova L, Tonolini M. Ultrasound of thyroid, parathyroid glands and neck lymph nodes. Eur Radiol. 2001;11:2411-2424.
16. Koike E, Noguchi S, Yamashita H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg. 2001;136:334-337.
17. Kang HW, No JH, Chung JH, et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid. 2004;14:29-33.
18. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283-298.
19. Haber RS,Weiser KR, PritskerA, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid. 1997;7:363-367.
20. Schonberger J, Ruschoff J, Grimm D, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002;12:747-754.
21. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004;14:806-812.
22. 18F-FDG PET and non-iodine radiopharmaceuticals. Nucl Med Commun. 2004;25:891-895.
23. Rheingold SR, Neugut AI, Meadows AT. Secondary cancers: incidence, risk factors, and management. In: Kufe DW, Pollock RE, Weichselbaum RR, et al, eds. Cancer Medicine. Hamilton, Canada: BC Decker; 2003:2623-2631.
24. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:77-84.
25. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med. 2005;46:752-757.
26. 18F-fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005;23:7654-7659.